LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for Atopic Dermatitis
If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine The ...
Read moreIf authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine The ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.